The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a Multicentre Randomized Trial Investigating the Effects of High Dose Unfractionated Heparin on Angiographic Restenosis and Clinical Outcome - SHARP Prevention

Description:

The goal of this study was to assess the safety and efficacy of high-dose subcutaneous unfractionated heparin in the prevention of restenosis among patients after successful percutaneous transluminal coronary angioplasty (PTCA).